Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model

Tanuka Biswas, Xiang Gu, Junhua Yang, Lesley G. Ellies, Luzhe Sun

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Previous studies have suggested that TGF-β functions as a tumor promoter in metastatic, mesenchymal-like breast cancer cells and that TGF-β inhibitors can effectively abrogate tumor progression in several of these models. Here we report a novel observation with the use of genetic and pharmacological approaches, and murine mammary cell injection models in both syngeneic and immune compromised mice. We found that TGF-β receptor II (TβRII) knockdown in the MMTV-PyMT derived Py8119, a mesenchymal-like murine mammary tumor cell line, resulted in increased orthotopic tumor growth potential in a syngeneic background and a similar trend in an immune compromised background. Systemic treatment with a small-molecule TGF-β receptor I kinase inhibitor induced a trend towards increased metastatic colonization of distant organs following intracardiac inoculation of Py8119 cells, with little effect on the colonization of luminal-like Py230 cells, also derived from MMTV-PyMT tumors. Taken together, our data suggest that the attenuation of TGF-β signaling in mesenchymal-like mammary tumors does not necessarily inhibit their malignant potential, and anti-TGF-β therapeutic intervention requires greater precision in identifying molecular markers in tumors with an indication of functional TGF-β signaling.

Original languageEnglish (US)
Pages (from-to)129-138
Number of pages10
JournalCancer Letters
Volume346
Issue number1
DOIs
StatePublished - Apr 28 2014

Fingerprint

Tumor Cell Line
Breast Neoplasms
Neoplasms
Tumor Biomarkers
Carcinogens
Breast
Phosphotransferases
Observation
Pharmacology
Injections
Therapeutics
Growth

Keywords

  • Metastasis
  • MMTV-PyMT mammary tumor
  • Syngeneic model
  • TGF-β

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. / Biswas, Tanuka; Gu, Xiang; Yang, Junhua; Ellies, Lesley G.; Sun, Luzhe.

In: Cancer Letters, Vol. 346, No. 1, 28.04.2014, p. 129-138.

Research output: Contribution to journalArticle

Biswas, Tanuka ; Gu, Xiang ; Yang, Junhua ; Ellies, Lesley G. ; Sun, Luzhe. / Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. In: Cancer Letters. 2014 ; Vol. 346, No. 1. pp. 129-138.
@article{5e70071b5f6346d98ac55269bf21aa4b,
title = "Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model",
abstract = "Previous studies have suggested that TGF-β functions as a tumor promoter in metastatic, mesenchymal-like breast cancer cells and that TGF-β inhibitors can effectively abrogate tumor progression in several of these models. Here we report a novel observation with the use of genetic and pharmacological approaches, and murine mammary cell injection models in both syngeneic and immune compromised mice. We found that TGF-β receptor II (TβRII) knockdown in the MMTV-PyMT derived Py8119, a mesenchymal-like murine mammary tumor cell line, resulted in increased orthotopic tumor growth potential in a syngeneic background and a similar trend in an immune compromised background. Systemic treatment with a small-molecule TGF-β receptor I kinase inhibitor induced a trend towards increased metastatic colonization of distant organs following intracardiac inoculation of Py8119 cells, with little effect on the colonization of luminal-like Py230 cells, also derived from MMTV-PyMT tumors. Taken together, our data suggest that the attenuation of TGF-β signaling in mesenchymal-like mammary tumors does not necessarily inhibit their malignant potential, and anti-TGF-β therapeutic intervention requires greater precision in identifying molecular markers in tumors with an indication of functional TGF-β signaling.",
keywords = "Metastasis, MMTV-PyMT mammary tumor, Syngeneic model, TGF-β",
author = "Tanuka Biswas and Xiang Gu and Junhua Yang and Ellies, {Lesley G.} and Luzhe Sun",
year = "2014",
month = "4",
day = "28",
doi = "10.1016/j.canlet.2013.12.018",
language = "English (US)",
volume = "346",
pages = "129--138",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model

AU - Biswas, Tanuka

AU - Gu, Xiang

AU - Yang, Junhua

AU - Ellies, Lesley G.

AU - Sun, Luzhe

PY - 2014/4/28

Y1 - 2014/4/28

N2 - Previous studies have suggested that TGF-β functions as a tumor promoter in metastatic, mesenchymal-like breast cancer cells and that TGF-β inhibitors can effectively abrogate tumor progression in several of these models. Here we report a novel observation with the use of genetic and pharmacological approaches, and murine mammary cell injection models in both syngeneic and immune compromised mice. We found that TGF-β receptor II (TβRII) knockdown in the MMTV-PyMT derived Py8119, a mesenchymal-like murine mammary tumor cell line, resulted in increased orthotopic tumor growth potential in a syngeneic background and a similar trend in an immune compromised background. Systemic treatment with a small-molecule TGF-β receptor I kinase inhibitor induced a trend towards increased metastatic colonization of distant organs following intracardiac inoculation of Py8119 cells, with little effect on the colonization of luminal-like Py230 cells, also derived from MMTV-PyMT tumors. Taken together, our data suggest that the attenuation of TGF-β signaling in mesenchymal-like mammary tumors does not necessarily inhibit their malignant potential, and anti-TGF-β therapeutic intervention requires greater precision in identifying molecular markers in tumors with an indication of functional TGF-β signaling.

AB - Previous studies have suggested that TGF-β functions as a tumor promoter in metastatic, mesenchymal-like breast cancer cells and that TGF-β inhibitors can effectively abrogate tumor progression in several of these models. Here we report a novel observation with the use of genetic and pharmacological approaches, and murine mammary cell injection models in both syngeneic and immune compromised mice. We found that TGF-β receptor II (TβRII) knockdown in the MMTV-PyMT derived Py8119, a mesenchymal-like murine mammary tumor cell line, resulted in increased orthotopic tumor growth potential in a syngeneic background and a similar trend in an immune compromised background. Systemic treatment with a small-molecule TGF-β receptor I kinase inhibitor induced a trend towards increased metastatic colonization of distant organs following intracardiac inoculation of Py8119 cells, with little effect on the colonization of luminal-like Py230 cells, also derived from MMTV-PyMT tumors. Taken together, our data suggest that the attenuation of TGF-β signaling in mesenchymal-like mammary tumors does not necessarily inhibit their malignant potential, and anti-TGF-β therapeutic intervention requires greater precision in identifying molecular markers in tumors with an indication of functional TGF-β signaling.

KW - Metastasis

KW - MMTV-PyMT mammary tumor

KW - Syngeneic model

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84896708967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896708967&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.12.018

DO - 10.1016/j.canlet.2013.12.018

M3 - Article

C2 - 24368187

AN - SCOPUS:84896708967

VL - 346

SP - 129

EP - 138

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -